individualHealthcareGlobal (with specific prevalence data for North America and China)

Patients with Methylmalonic Acidemia (MMAemia)

Individuals with a rare inherited disorder characterized by the inability to properly break down certain proteins and fats.

National Organization for Rare Disorders — NORD

Patients with Methylmalonic Acidemia (MMA) have an autosomal recessive condition that disrupts the conversion of methylmalonyl-coenzyme A (CoA) to succinyl-CoA, leading to a potentially life-threatening buildup of harmful acids in the blood and organs.

Ideas that could help Patients with Methylmalonic Acidemia (MMAemia)

Exosome-Based Metabolic Enzyme Delivery System
A targeted delivery vehicle using engineered exosomes to transport methylmalonyl-CoA mutase or related enzymes across the blood-brain barrier to reduce intracerebral metabolite accumulation.
Why it helps: They suffer from profound neurological injury and cognitive dysfunction due to the accumulation of toxic metabolites in the brain that current systemic therapies cannot effectively reach.